Your search for tofacitinib returned 19 results

Active Filters

Click on a filter below to refine your search. Remove a filter to broaden your search.

Post remove
Drugs in the Pipeline remove

Your search for tofacitinib returned 19 results

Sort Results:

Relevant Recent
Drugs in the Pipeline

Tofacitinib Effective in Phase 3 Psoriasis Retreatment Study

Pfizer announced results from the OPT (Oral treatment Psoriasis Trial) Retreatment study (A3921111) assessing tofacitinib for the treatment of adults with moderate-to-severe chronic plaque psoriasis.
Drugs in the Pipeline

Positive Results for Oral Tofacitinib in Ulcerative Colitis Presented

Pfizer announced detailed results from the first 2 pivotal Phase 3 trials of the OCTAVE program evaluating oral tofacitinib 10mg twice daily in inducing remission in adults with moderately to severely active ulcerative colitis (UC). Findings were orally presented at the 11th Congress of ECCO Scientific Session.
Drugs in the Pipeline

Phase 3 Trial Update of Tofacitinib for Rheumatoid Arthritis

Pfizer announced top-line results from ORAL Start (A3921069), a Phase 3 study of the investigational agent tofacitinib in the treatment of adults with moderate-to-severe active rheumatoid arthritis (RA).
Drugs in the Pipeline

Complete Response Letter Issued for Xeljanz on New Indication

The FDA has issued a Complete Response Letter (CRL) for the supplemental New Drug Application (sNDA) for Xeljanz (tofacitinib citrate; Pfizer) for the treatment of adults with moderate to severe chronic plaque psoriasis.